Edwards Lifesciences Analysts Improve Their Forecasts After Stronger-Than-Anticipated Q2 Outcomes – Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences Company EW reported better-than-expected second-quarter monetary outcomes on Thursday.

Edwards Lifesciences posted adjusted earnings of 67 cents per share, beating market estimates of 62 cents per share. The corporate’s quarterly gross sales got here in at $1.532 billion versus expectations of $1.488 billion.

Edwards Lifesciences affirmed FY2025 adjusted EPS steerage of $2.40-$2.50 and raised FY2025 gross sales steerage from $5.70 billion-$6.10 billion to $5.90 billion-$6.10 billion.

“We’re happy to report robust second quarter outcomes that delivered double-digit gross sales progress. Primarily based on our better-than-expected first half efficiency and the numerous catalysts throughout our portfolio, we’re assured in our full-year outlook and are elevating our gross sales and EPS steerage,” mentioned Bernard Zovighian, CEO. “Edwards is more and more distinguished by our balanced portfolio of main therapies throughout aortic, mitral and tricuspid which can place us for management for a few years to return as we assist much more sufferers all over the world.”

Edwards Lifesciences shares gained 5.1% to commerce at $79.51 on Friday.

These analysts made modifications to their value targets on Edwards Lifesciences following earnings announcement.

• Baird analyst David Rescott maintained Edwards Lifesciences with a Impartial and raised the worth goal from $78 to $79.
• Deutsche Financial institution analyst Pito Chickering maintained the inventory with a Purchase and boosted the worth goal from $85 to $94.
• Evercore ISI Group analyst Vijay Kumar maintained Edwards Lifesciences with an In-Line score and raised the worth goal from $77 to $80.

Contemplating shopping for EW inventory? Right here’s what analysts assume:

Learn This Subsequent:

Photograph by way of Shutterstock